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OBJECTIVE—In women with gestational diabetes mellitus, who were randomized to metfor-
min or insulin treatment, pregnancy outcomes were similar (Metformin in Gestational diabetes
[MiG] trial). Metformin crosses the placenta, so it is important to assess potential effects on
growth of the children.
RESEARCH DESIGN AND METHODS—In Auckland, New Zealand, and Adelaide,
Australia, women who had participated in the MiG trial were reviewed when their children were
2 years old. Body composition was measured in 154 and 164 children whose mothers had been
randomized tometformin and insulin, respectively. Children were assessed with anthropometry,
bioimpedance, and dual energy X-ray absorptiometry (DEXA), using standard methods.
RESULTS—The children were similar for baseline maternal characteristics and pregnancy
outcomes. In the metformin group, compared with the insulin group, children had larger
mid-upper arm circumferences (17.2 6 1.5 vs. 16.7 6 1.5 cm; P = 0.002) and subscapular
(6.36 1.9 vs. 6.06 1.7 mm; P = 0.02) and biceps skinfolds (6.036 1.9 vs. 5.66 1.7 mm; P =
0.04). Total fat mass and percentage body fat assessed by bioimpedance (n = 221) and DEXA (n =
114) were not different.
CONCLUSIONS—Children exposed to metformin had larger measures of subcutaneous
fat, but overall body fat was the same as in children whose mothers were treated with insulin
alone. Further follow-up is required to examine whether these ﬁndings persist into later life
and whether children exposed to metformin will develop less visceral fat and be more
insulin sensitive. If so, this would have signiﬁcant implications for the current pandemic of
diabetes.
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TheMetformin in Gestational diabetes(MiG) trial prospectively comparedpregnancy outcomes in women with
gestational diabetes mellitus (GDM) ran-
domized to either metformin (plus sup-
plemental insulin as required) or insulin
treatment. The primary outcome, a com-
posite of neonatal complications, was not
signiﬁcantly different between the treat-
ment arms (1). Secondary outcomes, in-
cluding body anthropometry at birth,
were also not different between the treat-
ment arms.
Metformin crosses the placenta in
signiﬁcant amounts, so although neonatal
outcomes are reassuring, it is important to
examine longer term outcomes, such as
body composition in childhood (2). It is
known that offspring of women with di-
abetes have an increased fat mass at birth
but not an increase in fat-free mass (FFM)
(3). An explanation of this ﬁnding may be
that because of continued exposure to nu-
trient excess in utero, the subcutaneous
fat stores become overloaded and, thus,
the fetus develops leptin and insulin re-
sistance and deposits excess nutrients as
ectopic fat (4). Reduced insulin sensitivity
has been demonstrated in cord blood
of infants exposed to maternal hypergly-
cemia (5). In a similar manner, infants of
obese women, who are also exposed to nu-
trient excess, have an increased fat mass at
birth and have been shown to be insulin
resistant (6). It is possible that metformin
exposure in utero might lead to improved
insulin action in the fetus, resulting in a
metabolically healthier pattern of growth,
with more subcutaneous fat stores devel-
oping and less ectopic fat (4,7,8).
The aim of The Offspring Follow-Up
(TOFU) study at 2 years of age was to
compare body composition in children of
women who participated in the MiG trial
and, in particular, to comparemeasures of
adiposity. Our hypothesis was that chil-
dren whose mothers had been random-
ized to metformin treatment would have
reduced central adiposity compared with
children whose mothers had been ran-
domized to insulin.
RESEARCH DESIGN AND
METHODS—In the MiG trial, 751
women with GDM who required medi-
cation to control their hyperglycemia
were randomized to either metformin or
insulin treatment; their pregnancy out-
comes have been reported (1). From two
recruiting sites in Auckland, New Zealand,
and one site in Adelaide, Australia, women
who had consented to further follow-up
were contacted by telephone at approxi-
mately the time of the child’s second birth-
day to explain the follow-up study and
to conﬁrm that they were still agreeable
to participate. In Auckland, a home visit
was arranged for the ﬁrst part of the
assessment during which maternal inter-
views and simple anthropometry mea-
surements of the mother and child were
made. A follow-up appointment was
made within 1 to 2 weeks of the home visit
to attend the Liggins Institute, University of
Auckland, for the child to have a physical
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examination, a neurodevelopmental as-
sessment, and a total body dual energy
X-ray absorptiometry (DEXA) measure-
ment. In Adelaide, women and their chil-
dren were invited to the hospital and all
the assessments were performed there.
This follow-up study had ethical approval
at each contributing site, and written in-
formed consent was again obtained for
each participant. The study was registered
prior to its initiation under the Australian
New Zealand Clinical Trials Registry
(ACTRN12605000311651).
Questionnaires were completed by
trained researchers, including assessment
of the family’s socioeconomic conditions,
home environment, any drug and alcohol
intake, and health of the mother and
child. Diet was assessed by 24-h recall
and food frequency questionnaires. Usual
activity of the children was assessed by a
24-h activity diary. The child underwent a
general physical examination by a pediatri-
cian and a neurodevelopmental assessment
by a psychologist. The neurodevelopmen-
tal ﬁndings and detailed diet and activity
assessments will be reported separately.
Anthropometry measurements of the
mother and child included weight, height,
leg length, head, chest, waist, hip and mid-
upper arm circumferences, and biceps,
triceps, and subscapular skinfolds. Skin-
folds were performed with a Holtain skin-
fold caliper (Holtain Ltd., Crymych, U.K.).
The method for each measurement was
based on those used in a New Zealand
Children’s Nutrition Survey (http://www.
moh.govt.nz/moh.nsf/0/064234A7283A
0478CC256DD60000AB4C/$Fi le /
nzfoodnzchildren.pdf) and detailed in the
studymanual. Training of study personnel
was undertaken by a single person in
Auckland to maintain consistency across
sites. All measurements were repeated
twice and the average calculated. A further
measurement was made if the difference in
measures was .0.5 cm (height and cir-
cumferences) or .0.5 mm (skinfolds),
and the average of the two closest measures
was calculated and used in the analysis.
Hand-to-foot single-frequency (50
kHz) bioimpedance analysis (BIA; BIM4,
Impedimed, Queensland, Australia) of
the child was performed with the child
lying supine. Areas on the hand and foot
where electrodes were to be placed were
ﬁrst cleaned with alcohol. The current
electrodes were placed on the hand on the
distal portion of the second metacarpal
and on the foot over the distal portion
of the second metatarsal. The sensing
electrodes were placed at the anterior
ankle between the tibial andﬁbularmalleoli
and at the posterior wrist between the
styloid processes of the radius and ulna.
The measurements were repeated up to
three times until they were stable to
within one ohm. The average resistance
value was used in the prediction equa-
tion below. A BIA measurement was un-
dertaken similarly in the mother, and the
FFM was calculated as FFM = 29.53 +
0.69stature2/resistance + 0.17weight +
0.02resistance (9).
If consented to separately, a DEXA
whole body scan of the child was per-
formed on a Lunar Prodigy 2000 scanner
(software version 4.80 3 6.50, General
Electric, Madison, WI). Each scan was
graded 1, 2, or 3 for quality by a single
person in Auckland and a single person in
Adelaide. Scans that were graded 3 (poor
quality) were excluded from this analysis.
As well as total fat, lean, and bone mineral
content, an abdominal and thigh area
for area fat content was calculated.
Abdominal and thigh regions of interest
were deﬁned by the criteria of Ley et al.
(10) The abdominal fat measure was ob-
tained from analysis of a region positioned
with the lower horizontal border on top
of the iliac crest and the upper border
approximately parallel with the junction
of the T12 and L1 vertebrae. The sides of
this region were adjusted to include the
maximum amount of abdominal tissue.
The thigh measure was obtained by ana-
lyzing an area of identical height placed
over the thighs with the upper horizontal
border positioned immediately below
the ischial tuberosities. The lateral mar-
gins were adjusted to follow the shape of
the thighs. The DEXA FFM was used as
the criterion for the development of a
prediction equation for bioimpedance
FFM based on the following predictor
values: weight, height2/resistance, sex
(dummy coded with girls = 0 and
boys = 1), and age. The equation devel-
oped was as follows:
Figure 1—Offspring followed up from the MiG trial.
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FFM DEXAkg ¼  0:894þ 0:421H2=
R þ 0:268Wtþ 0:338Sexþ 0:064Age
(R2 = 0.857, SEE [standard error of the es-
timate] = 0.559 kg), where H is height (cm),
R is resistance (V), Wt is weight (kg), Sex
(0 = girls, 1 = boys), and Age (months) (11).
The bioimpedance and DEXA mea-
sures of the child were performed in the
morning before morning tea with the
child wearing a T-shirt and dry disposable
nappy.
Statistical analysis
A follow-up rate of 50% was anticipated,
recognizing that it might be difﬁcult, for
various social reasons, to maintain con-
tact with the MiG trial population, as
others have described and highlighted by
the initial 6–8 week postpartum follow-
up, which was achieved in 75%.
Power calculations. A study of 240 chil-
dren (120 in each arm) would allow de-
tection of a 2% difference in body fat
percent (based on an estimated body fat
of 24 6 4%) with 97% power and, thus,
allowing a clinically meaningful analysis of
the groups with respect to body composi-
tion. A study of 37 children in each treat-
ment arm would have 80% power to
detect a 2% difference in body fat percent.
Continuous variables were examined
for normal distribution. For all data
presented, the distributions were normal.
Continuous variables are presented as
mean 6 SD. One-way ANOVA was used
to test for differences in groupmeans, and
post hoc t tests were used to determine
which groups were different. The signiﬁ-
cance level was set at 5%. ANCOVA was
used to adjust for height, weight, and age
when examining differences in fat mass
and FFM among ethnic groups.
RESULTS—Of the women recruited
into MiG at the two Auckland sites, 189
of 282 (67%) and 33 of 114 (28.9%) were
seen for follow-up. In Adelaide, 101 of
181 (55.8%) were seen, giving a total of
323 women (Fig. 1). Body composition
measurements were performed in 318
children, of whom 154 mothers and 164
mothers had been randomized to metfor-
min and insulin treatment during preg-
nancy, respectively. A bioimpedance
measurement was performed in 103 and
118 children in the metformin and insulin
arms, respectively. DEXA measurements
were performed in 140 children: 114 grade
1 and 2 scans were analyzed, 57 in each
treatment arm.
The children seen at 2 years of age
included a smaller proportion of those
of Polynesian ethnicity compared with
the total MiG population (14 vs. 20%,
P = 0.02). Also, children seen for follow-
up had had a shorter crown-rump length
at birth (33.0 vs. 33.5 cm, P = 0.005) and
smaller triceps skinfolds (4.80 vs. 5.15
mm, P = 0.0002) and subscapular skin-
folds (4.95 vs. 5.20 mm, P = 0.07) at birth
than the total group. All other baseline
characteristics of the mothers and chil-
dren and trial outcome measures were
not different between the follow-up
group and the total MiG population
(data not shown).
In the children seen at 2 years of age,
there were no differences between the
groups in the baseline characteristics of
the mother at randomization to treatment
(Table 1). There were also no differences
in pregnancy outcomes between the met-
formin and insulin follow-up groups, in-
cluding the MiG trial primary outcome
composite of neonatal complications
(31.2 vs. 34.7%, P = 0.97), admission to
the neonatal unit (17.5 vs. 18.3%, P =
0.97), and admission for .24 h (11.7
vs. 11.6%, P = 0.98). In addition, there
were no differences between the groups in
measurements at birth, maternal glucose
control during pregnancy, and rates of
breast feeding at 6–8 weeks postpartum
(Table 2). Follow-upmaternal anthropom-
etry was not different between the two
groups; maternal BIA showed higher FFM
in the metformin group, but percentage
body fat was not different (Table 3).
Body composition measurements at
2 years of age showed three signiﬁcant
differences (Table 3). The upper-arm cir-
cumference was larger in the metformin
group (P = 0.002), and subscapular skin-
folds and biceps skinfolds were bigger
(P = 0.02 and P = 0.04, respectively).
These results were explored further to
conﬁrm that the differences related to
treatment. After adjusting for age, sex,
ethnicity, and maternal glucose control
during pregnancy, the P values were:
upper-arm circumference, P = 0.005; sub-
scapular skinfold, P = 0.01; and biceps
skinfold, P = 0.02. There were no differ-
ences in DEXA measures between the
two groups by unadjusted and adjusted
analysis. This included total and regional
fat measures. Bioimpedance measures also
showed no difference between the metfor-
min and insulin group in FFM or percent-
age fat.
CONCLUSIONS—This study de-
scribes the body composition in a unique
population of 2-year-olds whose mothers
had GDM and were randomized to treat-
ment with metformin or insulin during
pregnancy. The groups were matched for
baseline maternal characteristics, maternal
glycemia, and pregnancy outcomes.
Our initial hypothesis was that met-
formin exposure in utero would be asso-
ciated with less central fat and, therefore,
Table 1—Children assessed at age 2 years: the maternal baseline characteristics at




(n = 164) P value
Age (years) 39.4 6 5.2 38.9 6 5 0.32
BMI (kg/m2)
At booking (before 20 weeks’ gestation) 31.8 6 8.2 31.1 6 10 0.47
At recruitment 33.4 6 12 31.6 6 10 0.12
Gestational age at recruitment (weeks) 30.4 6 3.3 30.0 6 3.3 0.58
Ethnicity (self-reported) 0.46
European/Caucasian 88 (57.1) 78 (47.6)
Polynesian 21 (13.6) 26 (15.9)
Indian 22 (14.3) 34 (20.7)
Chinese and other Southeast Asian 15 (9.7) 16 (9.8)
Other or mixed 8 (5.2) 10 (6.1)
Tertiary education 79 (51.3) 96 (58.5) 0.24
Smoking in pregnancy 16 (10.4) 10 (6.1) 0.23
Chronic hypertension 20 (13.0) 17 (10.4) 0.58
75-g OGTT result
Fasting plasma glucose (mmol/L) 5.5 6 1 5.6 6 1 0.56
2-h plasma glucose(mmol/L) 9.6 6 2 9.5 6 2 0.72
HbA1c at recruitment (%) 5.7 6 0.58 5.7 6 0.67 0.96
Data expressed as mean 6 SD or n (%). OGTT, oral glucose tolerance test.
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less insulin resistance in the offspring.
However, we found no differences be-
tween groups in central fat measures,
total fat mass, percentage body fat, or
central-to-peripheral fat as measured by
waist-to-hip ratio and DEXA-calculated
abdominal-to-thigh fat ratios. Instead, we
found that the children who were exposed
to metformin in utero had larger upper-
arm circumferences and bigger biceps and
subscapular skinfolds. This suggests that
exposure to metformin in utero has led to
more fat being stored in subcutaneous
sites, whichmay in turnmean there is less
ectopic or visceral fat in these children.
These ﬁndings are important for two
reasons: ﬁrst, they suggest that maternal
metformin treatment during pregnancy
may lead to a more favorable pattern of fat
distribution for exposed children; sec-
ond, they suggest that simple measures
of central fat may not be adequate for
determining the potential effects of in
utero exposure to metformin. The central
fat measures used in this study provided a
combined measure of subcutaneous and
visceral fat, so further studies will be
needed to conﬁrm whether the children
exposed tometformin have less visceral fat.
Size and location of fat cells are
important predictors of insulin resistance
and adverse metabolic consequences of
obesity (4,8,12). Subcutaneous fat cells
provide an important physiological store
of extra nutrients. They have a limited ca-
pacity and are normally under homeo-
static regulation, providing feedback
about food intake and satiety. In situa-
tions of ongoing excessive nutrient in-
take, the adipocytes become large and
dysfunctional and excess fat is deposited
in visceral adipocyte depots, which
readily release fatty acids and inﬂamma-
tory adipocytokines (12). These changes
are associated with insulin resistance, as
opposed to insulin-sensitive obesity,
which is associated with proportionally
more healthy subcutaneous fat cells and
less visceral fat (8,13,14). A more insulin-
sensitive pattern of growth would be a
plausible consequence of metformin ex-
posure in utero, based on our under-
standing of metformin action (7). To
examine this question further, ongoing
follow-up will be important to determine
whether differences persist and to measure
visceral and subcutaneous fat and insulin
sensitivity. Longitudinal follow-up is also
important in that postnatal inﬂuences on
growth may override any effect of metfor-
min exposure during late pregnancy (15).
There are no other similar studies for
comparison, so our data are novel. There
are studies looking at subsequent growth
of children whose mothers have had di-
abetes in pregnancy (16–20). Compared
with children whose mothers did not
have diabetes, they were more likely to
be obese and have features of insulin re-
sistance, which is felt to be the result of
both genetic and intrauterine and post-
natal environmental factors. It is possible
that there are critical windows where in-
terventionmight improve these outcomes
(21). There are two randomized trials
showing that treatment of mild GDM
(predominantly with diet) compared
with standard pregnancy care was associ-
ated with improved pregnancy outcomes
(22,23), but initial follow-up of children
in one trial did not show a signiﬁcant dif-
ference in BMI at 4–5 years of age (24). It
is unclear whether the intervention in
pregnancy was too late or inadequate or
whether a difference will appear at subse-
quent follow-up. More detailed measures
of visceral fat in those children would also
be of interest. A further study has shown
that treating women with GDM resulted
in fewer overweight children at 5–7 years
of age compared with children whose
mothers had elevated glucose tolerance
test results during pregnancy but did
not reach the threshold for a diagnosis
and treatment of GDM (25). These data
also highlight the need for further studies
looking at how different treatments for
GDM inﬂuence long-term outcomes to
better understand how to optimize the
health of future generations.
The major strength of this follow-up
study is that the offspring were well
matched, enabling valid comparisons
between treatment groups. Also, body




(n = 164) P value
Neonatal
Gestational age at birth (weeks) 38.4 6 1.3 38.5 6 1.2 0.32
Birth weight (g) 3,325 6 558 3,356 6 530 0.62
Birth weight percentile 52.8 6 29.1 52.2 6 30.8 0.87
Birth weight below 10th percentile 14 (9.1) 15 (9.1)
Birth weight above 90th percentile 20 (13.0) 23 (14.0)
Head circumference (cm) 34.8 6 1.5 34.8 6 1.5 0.98
Crown-heel length (cm) 50.1 6 2.6 50.3 6 2.4 0.60
Crown-rump length (cm) 33.0 6 2.6 32.9 6 2.5 0.55
Chest circumference (cm) 33.9 6 2.4 33.9 6 2.5 0.92
Abdominal circumference (cm) 32.8 6 2.8 32.4 6 3.0 0.30
Mid-upper arm circumference (cm) 11.1 6 1.3 11.0 6 1.3 0.63
Triceps skinfold thickness (mm) 4.77 6 1.2 4.82 6 1.1 0.72
Subscapular skinfold thickness (mm) 4.96 6 1.2 4.94 6 1.1 0.93
Ponderal index (birth weight [g] 3
100/crown-heel length [cm]3) 2.63 6 0.3 2.63 6 0.28 0.85
Maternal
Glycemic control from randomization until delivery
Mean fasting capillary glucose 0.71
Tertile 1 (mean 4.6 6 0.3 mmol/L) 55 (35.7) 66 (40.2)
Tertile 2 (mean 5.1 6 0.1 mmol/L) 61 (39.6) 64 (39.0)
Tertile 3 (mean 5.9 6 0.6 mmol/L) 36 (23.4) 34 (20.7)
Mean postprandial capillary glucose 0.69
Tertile 1 (mean 5.6 6 0.2 mmol/L) 67 (43.5) 65 (39.6)
Tertile 2 (mean 6.2 6 0.2 mmol/L) 51 (33.1) 57 (34.8)
Tertile 3 (mean 7.2 6 0.7 mmol/L) 34 (22.1) 42 (25.6)
Hypertensive complications
Gestational hypertension 7 (4.5) 5 (3.0) 0.69
Preeclampsia 5 (3.2) 8 (4.9) 0.65
Infant feeding 6–8 weeks postpartum 0.72
Breast feeding 74 (48.1) 84 (51.2)
Bottle feeding 30 (19.5) 35 (21.3)
Both breast and bottle 42 (27.3) 39 (23.8)
Not seen 8 (5.2) 6 (3.7)
Data expressed as mean 6 SD or n (%) unless otherwise detailed.
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composition was measured by several
methods, and the differences found were
consistent with a biologically plausible ef-
fect of metformin. A potential limitation is
the low follow-up rate of the total MiG
cohort. The follow-up group did have fewer
Polynesian children, and as a group they
had a shorter crown-rump length and
smaller subscapular and triceps skinfolds
at birth, compared with the total group.
Otherwise, they were representative of the
whole group and the studywas adequately
powered to explore differences in body
composition. Also, additional analyses
were performed to examine whether other
potential confounders were contributing
to the ﬁndings, but they conﬁrmed that
the differences related to treatment.
In conclusion, 2-year-old offspring of
women with GDM, who were exposed to
metformin in utero, had larger subscapular
and biceps skinfolds but showed no dif-
ference in total or percentage body fat
compared with children whose mothers
were treated during pregnancy with insulin
alone. Whether this will translate to a more
insulin-sensitive pattern of growth requires
further examination. The ﬁndings are re-
assuring for clinicians who are using met-
formin during pregnancy.
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